Role of metabolism in arsenic toxicity

被引:231
作者
Vahter, M [1 ]
Concha, G [1 ]
机构
[1] Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden
来源
PHARMACOLOGY & TOXICOLOGY | 2001年 / 89卷 / 01期
关键词
D O I
10.1034/j.1600-0773.2001.d01-128.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In humans, as in most mammalian species, inorganic arsenic is methylated to methylarsonic acid (MMA) and dimethylarsinic acid (DMA) by alternating reduction of pentavalent arsenic to trivalent and addition of a methyl group from S-adenosylmethionine. The methylation of inorganic arsenic may be considered a detoxification mechanism, as the end metabolites, MMA and DMA, are less reactive with tissue constituents, less toxic, and more readily excreted in the urine than is inorganic arsenic, especially the trivalent form (As-III, arsenite). The latter is highly reactive with tissue components, due to its strong affinity for sulfhydryl groups. Thus, following exposure to As-V, the first step in the biotransformation, i.e. the reduction to As-III, may be considered a bioactivation. Also, reactive intermediate metabolites of high toxicity, mainly MMA(III), may be formed and distributed to tissues. Low levels of MMA(III) and DMA(III) have been detected in urine of individuals chronically exposed to inorganic arsenic via drinking water. However, the contribution of MMA(III) and DMA(III) to the toxicity observed after intake of inorganic arsenic by humans remains to be elucidated. The major route of excretion of arsenic is via the kidneys. Evaluation of the methylation of arsenic is mainly based on the relative amounts of the different metabolites in urine. On average human urine contains 10-30% inorganic arsenic, 10-20% MMA and 60-80% DMA.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 68 条
[1]  
[Anonymous], 1999, ARS DRINK WAT
[2]  
ANUNDI I, 1982, FEBS LETT, V45, P285
[3]   Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic [J].
Aposhian, HV ;
Gurzau, ES ;
Le, XC ;
Gurzau, A ;
Healy, SM ;
Lu, XF ;
Ma, MS ;
Yip, L ;
Zakharyan, RA ;
Maiorino, RM ;
Dart, RC ;
Tircus, MG ;
Gonzalez-Ramirez, D ;
Morgan, DL ;
Avram, D ;
Aposhian, MM .
CHEMICAL RESEARCH IN TOXICOLOGY, 2000, 13 (08) :693-697
[4]   Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity [J].
Aposhian, HV .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :397-419
[5]   ARSENIC BINDING-PROTEINS OF MAMMALIAN SYSTEMS .1. ISOLATION OF 3 ARSENITE-BINDING PROTEINS OF RABBIT LIVER [J].
BOGDAN, GM ;
SAMPAYOREYES, A ;
APOSHIAN, HV .
TOXICOLOGY, 1994, 93 (2-3) :175-193
[6]   STUDY OF FACTORS INFLUENCING THE INVIVO METHYLATION OF INORGANIC ARSENIC IN RATS [J].
BUCHET, JP ;
LAUWERYS, R .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1987, 91 (01) :65-74
[7]   ROLE OF THIOLS IN THE INVITRO METHYLATION OF INORGANIC ARSENIC BY RAT-LIVER CYTOSOL [J].
BUCHET, JP ;
LAUWERYS, R .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (16) :3149-3153
[8]   COMPARISON OF THE URINARY-EXCRETION OF ARSENIC METABOLITES AFTER A SINGLE ORAL DOSE OF SODIUM ARSENITE, MONOMETHYLARSONATE, OR DIMETHYLARSINATE IN MAN [J].
BUCHET, JP ;
LAUWERYS, R ;
ROELS, H .
INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 1981, 48 (01) :71-79
[9]   Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan [J].
Chiou, HY ;
Hsueh, YM ;
Hsieh, LL ;
Hsu, LI ;
Hsu, YH ;
Hsieh, FI ;
Wei, ML ;
Chen, HC ;
Yang, HT ;
Leu, LC ;
Chu, TH ;
ChenWu, C ;
Yang, MH ;
Chen, CJ .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 1997, 386 (03) :197-207
[10]   Metabolism of inorganic arsenic in children with chronic high arsenic exposure in northern Argentina [J].
Concha, G ;
Nermell, B ;
Vahter, M .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1998, 106 (06) :355-359